Study identifier:D5160C00002
ClinicalTrials.gov identifier:NCT02094261
EudraCT identifier:2014-000531-17
CTIS identifier:N/A
Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic NSCLC whose Disease has Progressed with Previous EGFR TKI and whose Tumours are EGFR and T790M Mutation Positive
Non Small Cell Lung Cancer
Phase 2
No
AZD9291
All
210
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2023 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD9291 Once daily tablet 80 mg | Drug: AZD9291 Once daily tablet 80 mg |